NCT00964730View on ClinicalTrials.gov

A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm

PHASE1CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

February 28, 2010

Conditions
Healthy
Interventions
DRUG

Talampanel

titrated to 50mg three times a day over 9 days and a single dose administered on Day 10

DRUG

Moxifloxacin

Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10

DRUG

Placebo

administered three times a day over 9 days and a single dose administered on Day 10

Trial Locations (1)

58104

Cetero Research - Fargo, Fargo

Sponsors
All Listed Sponsors
collaborator

Cetero Research, San Antonio

NETWORK

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00964730 - A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm | Biotech Hunter | Biotech Hunter